Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Described herein is a peptide, a multimodal peptide ligand imaging agent and methods for use in tumor targeting, tumor visualization, drug delivery and as an imaging ligand. The invention further provides for a theranostic peptide agent and methods for use in the treatment of cancer and/or inflammation in a subject.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Disclosed herein is a method of analyzing flow cytometry data for cells derived from homogenized whole tumor samples.

The present invention is directed to methods of diagnosing, prognosing, and managing treatment of cancer in a subject. These methods involve selecting a subject having cancer and obtaining, from the selected subject a population of either exomeres having a diameter less than 50 nm, small exosomes having a diameter of 60-80 nm, or large exosomes having a diameter of 90-120 nm, The exomeres, small exosomes, or large exosomes are recovered from the sample, and the exomeres, small exosomes, or large exosomes or portions thereof are contacted with one or more reagents suitable to detect: (1) higher or lower levels, relative to a standard for subjects not having cancer, or the presence or absence, of one or more proteins contained in said exomeres, small exosomes, or large exosomes, (2) higher or lower levels, relative to a standard for subjects not having cancer, or the presence or absence, of one or more N-giyeans contained In said exomeres, small exosomes, or large exosomes, (3) higher or lower levels, relative to a standard for subjects not having cancer, or the presence or absence, of one or mom lipids contained in said exomeres, small exosomes, or large exosomes, (4) the presence or absence of one or mom genetic mutations in nucleic acid molecules associated with cancer and contained in said exomeres, small exosomes, or large exosomes, or (5) combinations thereof. Cancer is then diagnosed, prognosed, or treatment Is modified based on this information.

Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an OX40 agonist, a PD-1 pathway inhibitor, and a CTLA-4 inhibitor.